New oral antithrombotic agents for the prevention of deep venous thrombosis and pulmonary embolism in orthopedic surgery.
As the population ages and medical care, along with a functional life style, continues to improve the health of this group, the number of joint replacement surgeries will continue to rise each year in the United States. This growing volume carries with it the risk of venous thromboembolism associated with joint replacement surgery. The American College of Chest Physicians and the American Academy of Orthopedic Surgery have provided guidelines for preventing this complication with the use of warfarin, low molecular weight heparins, pentasaccharides, and aspirin. These agents have had variable efficacy and safety preventing postoperative and out-of-hospital venous thromboembolism. New classes of oral agents, which inhibit Factor II or Factor X, have been shown to be an effective and safe class of anticoagulants that do not require monitoring or have food and drug interactions. This paper will review the current data on the new oral anticoagulants in joint replacement surgery.
Merli
Geno J
GJ
Jefferson Vascular Center, Thomas Jefferson University Hospital, and Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. Geno.merli@jefferson.edu
D000284:Administration, Oral; D019643:Arthroplasty, Replacement / Q000009:adverse effects / Q000534:rehabilitation; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D011183:Postoperative Complications; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents